MKI67 and breast cancer: As we enter the multiomic era, these encouraging advancements in the fields of genomic and radiomic medicine look certain to be at the forefront of future diagnostics, prognostication, as well as therapeutic decision making in breast cancer management, and provide the potential to enhance/augment the current value of Ki-67 proliferation indices in breast tumour histopathological and immunohistochemical appraisal.